Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 10/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821212 | 0.97 | MAPT (0.66) | MAPTCTSKCTSLCTSBKLK7 | |
| SCHEMBL5500108 | 0.96 | SYK (0.58) | MAPTCTSKCTSLCTSBKLK7 | |
| SCHEMBL12247705 | 0.93 | MAPT (0.61) | MAPTCTSKCTSLCTSBKLK7 | |
| SCHEMBL699601 | 0.93 | MAPT (0.61) | MAPTCTSKCTSLCTSBKLK7 | |
| SCHEMBL29458828 | 0.86 | SYK (0.63) | MAPTCTSKCTSLCTSBSYK | |
| SCHEMBL24152311 | 0.86 | FOLH1 (0.58) | CTSKHTTTGM2FOLH1 | |
| SCHEMBL8607096 | 0.86 | FOLH1 (0.58) | CTSKHTTTGM2FOLH1 | |
| SCHEMBL13430791 | 0.85 | SYK (0.48) | MAPTCTSKCTSLCTSBKLK7 | |
| SCHEMBL13480482 | 0.85 | MAPT (0.65) | MAPTKLK7KLK5SYKHTT | |
| SCHEMBL16279355 | 0.85 | MAPT (0.60) | MAPTCTSKKLK7KLK5SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528137-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1539727-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | CYTOKINETICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7214800-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1539727-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1556357-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1553931-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060094735-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060004073-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6949538-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1556357-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1553931-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1539727-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040116400-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082567-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077668-A1 | Compounds, compositins, and methods | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004006865-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003106426-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003097053-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077668-A1 | Compounds, compositins, and methods | CEP170, PSAP, PACSIN2 | MAPT 1449/4885CTSK 1191/4885CTSL 1556/4885 |
| US-20060094735-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | MAPT 2954/4885CTSK 1172/4885CTSL 2514/4885 |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | KIF5B, KIF2C, KIF18A | MAPT 964/4885CTSK 287/4885CTSL 1117/4885 |
| US-20060004073-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | MAPT 2954/4885CTSK 1172/4885CTSL 2514/4885 |
| US-20040082567-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | MAPT 2954/4885CTSK 1172/4885CTSL 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.